Amarin Corp Plc (AMRN): http://www.fiercepharma.com/story/genzym...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	234
Posts	26887
Boards Moderated	0
Alias Born	01/12/2013

Biobillionair

Re: BRIG_88 post# 9061

Monday, 06/24/2013 3:08:56 PM

Monday, June 24, 2013 3:08:56 PM

http://www.fiercepharma.com/story/genzymes-176k-kynamro-price-undercuts-its-250k-plus-rival/2013-01-31

BRIG do you have $175,000 to spend on Isis Rx? LOL!!! 1/3 of the treatment group had flu like symptoms

KYNAMRO™ Long-term Data at ISA
KYNAMRO™ (mipomersen sodium) Data Presented
at XVI International Symposium on Atherosclerosis

Phase 3 Extension Study Highlights Long-term Safety and Efficacy in Patients with Familial Hypercholesterolemia (FH)

Genzyme and Isis announced today that new two-year data from a phase 3 long-term extension study of KYNAMROTM (mipomersen sodium) were presented at the XVI International Symposium on Atherosclerosis in Sydney, Australia. In the study, patients treated with KYNAMROTM for two years maintained robust reductions in LDL-C and all other Apo B containing atherogenic lipoproteins measured with a safety profile consistent with the phase 3 studies of KYNAMROTM.